VOYA Investment Management
ITCI

VOYA Investment Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

VOYA Investment Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-44,125
Closed -$5.82M – 2770
2025
Q1 		$5.82M Sell
44,125
-41,286
-48% -$5.15M 0.01% 905
2024
Q4 		$7.13M Buy
85,411
+10,444
+14% +$858K 0.01% 845
2024
Q3 		$5.49M Sell
74,967
-3,086
-4% -$232K 0.01% 969
2024
Q2 		$5.35M Sell
78,053
-92,429
-54% -$6.41M 0.01% 969
2024
Q1 		$11.8M Buy
170,482
+2,213
+1% +$152K 0.01% 700
2023
Q4 		$12.1M Buy
168,269
+14,363
+9% +$826K 0.01% 679
2023
Q3 		$8.02M Buy
153,906
+813
+0.5% +$47.4K 0.01% 785
2023
Q2 		$9.69M Buy
153,093
+9,105
+6% +$567K 0.01% 749
2023
Q1 		$7.8M Sell
143,988
-23
-0% -$1.11K 0.01% 809
2022
Q4 		$7.62M Buy
144,011
+1,078
+0.8% +$54K 0.01% 822
2022
Q3 		$6.65M Buy
142,933
+20,923
+17% +$1.09M 0.01% 847
2022
Q2 		$6.96M Buy
122,010
+16,228
+15% +$920K 0.02% 608
2022
Q1 		$6.47M Buy
105,782
+77,963
+280% +$4.05M 0.01% 762
2021
Q4 		$1.46M Buy
27,819
+13
+0% +$546 ﹤0.01% 1325
2021
Q3 		$1.04M Hold
27,806
– – ﹤0.01% 1542
2021
Q2 		$1.14M Sell
27,806
-1,544
-5% -$57.1K ﹤0.01% 1550
2021
Q1 		$996K Buy
29,350
+918
+3% +$31.8K ﹤0.01% 1587
2020
Q4 		$904K Buy
28,432
+6,575
+30% +$173K ﹤0.01% 1567
2020
Q3 		$561K Buy
21,857
+2,561
+13% +$58.4K ﹤0.01% 1602
2020
Q2 		$495K Sell
19,296
-6,564
-25% -$133K ﹤0.01% 1674
2020
Q1 		$397K Buy
25,860
+3,723
+17% +$80.9K ﹤0.01% 1763
2019
Q4 		$760K Buy
22,137
+2,659
+14% +$31.9K ﹤0.01% 1625
2019
Q3 		$146K Hold
19,478
– – ﹤0.01% 2314
2019
Q2 		$253K Hold
19,478
– – ﹤0.01% 2165
2019
Q1 		$237K Hold
19,478
– – ﹤0.01% 2182
2018
Q4 		$222K Buy
19,478
+1,031
+6% +$16.6K ﹤0.01% 2179
2018
Q3 		$400K Hold
18,447
– – ﹤0.01% 1979
2018
Q2 		$326K Buy
18,447
+381
+2% +$7.74K ﹤0.01% 2100
2018
Q1 		$380K Hold
18,066
– – ﹤0.01% 1971
2017
Q4 		$262K Buy
18,066
+1,155
+7% +$17.8K ﹤0.01% 2212
2017
Q3 		$267K Hold
16,911
– – ﹤0.01% 2233
2017
Q2 		$210K Buy
16,911
+2,338
+16% +$27.1K ﹤0.01% 2387
2017
Q1 		$237K Hold
14,573
– – ﹤0.01% 2187
2016
Q4 		$220K Hold
14,573
– – ﹤0.01% 2239
2016
Q3 		$222 Hold
14,573
– – ﹤0.01% 2225
2016
Q2 		$566K Buy
14,573
+4,824
+49% +$173K ﹤0.01% 1627
2016
Q1 		$271K Hold
9,749
– – ﹤0.01% 2056
2015
Q4 		$524K Hold
9,749
– – ﹤0.01% 1680
2015
Q3 		$390K Sell
9,749
-2,582
-21% -$84.2K ﹤0.01% 1882
2015
Q2 		$394K Hold
12,331
– – ﹤0.01% 2078
2015
Q1 		$294K Hold
12,331
– – ﹤0.01% 2235
2014
Q4 		$218K Hold
12,331
– – ﹤0.01% 2438
2014
Q3 		$169K Hold
12,331
– – ﹤0.01% 2535
2014
Q2 		$208K Buy
+12,331
New +$204K ﹤0.01% 2547

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

VOYA Investment Management's ITCI Position: Q2 2025 in Review

VOYA Investment Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 44,125 shares — an estimated $5.82M sold.

VOYA Investment Management first reported a position in ITCI in Q2 2014 and held it in 44 quarters. The position peaked at $12.1M in Q4 2023. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • VOYA Investment Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • VOYA Investment Management sold 44,125 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $5.82M.
  • VOYA Investment Management first reported a position in Intra-Cellular Therapies Inc. in Q2 2014 and held it in 44 quarters.
  • VOYA Investment Management's Intra-Cellular Therapies Inc. position peaked at $12.1M in Q4 2023.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on VOYA Investment Management's 13F filing for Q2 2025, filed 14 Aug 2025.